CF PHARMTECH (02652) has announced that the Group's overall business operations remain normal, maintaining profitability for three consecutive years. The Group anticipates achieving the following for 2025: (i) revenue between RMB 410 million and RMB 450 million; (ii) profit attributable to shareholders under International Financial Reporting Standards (IFRS) ranging from RMB 2 million to RMB 3 million; and (iii) an adjusted net profit (a non-IFRS measure) between RMB 30 million and RMB 35 million.

Since its listing, the Group has achieved several milestones, including key progress in innovative drug applications and the completion of brand volume reporting for a major national centralized procurement product. These steps are aimed at addressing market challenges and driving sustainable growth.

Key developments include: (a) The Marketing Authorization Application for budesonide nasal spray, along with the Investigational New Drug applications for ICF004 and ICF001, have been accepted by China's National Medical Products Administration. Furthermore, the clinical trial application for olopatadine mometasone nasal spray has been approved, strengthening the Group's product portfolio in the respiratory and nasal care sector.

(b) In line with the updated National Volume-Based Procurement (VBP) plan, brand volume reporting for CF017 (budesonide suspension for inhalation) in medical institutions has been completed. Hospital coverage has been expanded nationwide, and the procurement cycle is set to continue until the end of 2028.

(c) The company has been included in the Hang Seng Composite Index and the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. This is expected to enhance the trading liquidity of its H-shares.

(d) Pursuant to a general mandate granted in December 2025, the company has conducted several H-share repurchases. Subject to market conditions and funding arrangements, and in compliance with listing rules and applicable regulations, the company may consider further repurchases of H-shares.